Bone Biologics Corporation
BBLG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $7 | $2 | $0 |
| G&A Expenses | $2 | $3 | $0 | $0 |
| SG&A Expenses | $2 | $3 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $9 | $4 | $1 |
| Operating Income | -$4 | -$9 | -$4 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $2 | -$1 |
| Pre-Tax Income | -$4 | -$9 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$9 | -$1 | -$2 |
| % Margin | – | – | – | – |
| EPS | -4.83 | -34.01 | -31.15 | -37.35 |
| % Growth | 85.8% | -9.2% | 16.6% | – |
| EPS Diluted | -4.83 | -34.01 | -31.2 | -37.35 |
| Weighted Avg Shares Out | 2 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $4 | $9 | $0 | $0 |
| EBITDA | $0 | $0 | -$1 | -$1 |
| % Margin | – | – | – | – |